KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to ixazomib. In this study we examined factors respo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144825&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850189208011931648 |
|---|---|
| author | Nibedita Chattopadhyay Allison J Berger Erik Koenig Bret Bannerman James Garnsey Hugues Bernard Paul Hales Angel Maldonado Lopez Yu Yang Jill Donelan Kristen Jordan Stephen Tirrell Bradley Stringer Cindy Xia Greg Hather Katherine Galvin Mark Manfredi Nelson Rhodes Ben Amidon |
| author_facet | Nibedita Chattopadhyay Allison J Berger Erik Koenig Bret Bannerman James Garnsey Hugues Bernard Paul Hales Angel Maldonado Lopez Yu Yang Jill Donelan Kristen Jordan Stephen Tirrell Bradley Stringer Cindy Xia Greg Hather Katherine Galvin Mark Manfredi Nelson Rhodes Ben Amidon |
| author_sort | Nibedita Chattopadhyay |
| collection | DOAJ |
| description | In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to ixazomib. In this study we examined factors responsible for ixazomib sensitivity or resistance using mouse xenograft models. A survey of 14 non-small cell lung cancer (NSCLC) and 6 colon xenografts showed a striking relationship between ixazomib activity and KRAS genotype; tumors with wild-type (WT) KRAS were more sensitive to ixazomib than tumors harboring KRAS activating mutations. To confirm the association between KRAS genotype and ixazomib sensitivity, we used SW48 isogenic colon cancer cell lines. Either KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cells to generate cells that stably express activated KRAS. SW48 KRAS WT tumors, but neither SW48-KRAS-G13D tumors nor SW48-KRAS-G12V tumors, were sensitive to ixazomib in vivo. Since activated KRAS is known to be associated with metabolic reprogramming, we compared metabolite profiling of SW48-WT and SW48-KRAS-G13D tumors treated with or without ixazomib. Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors. Ixazomib treatment resulted in significant metabolic regulation, and some of these changes were specific to KRAS WT tumors. Depletion of free amino acid pools and activation of GCN2-eIF2α-pathways were observed both in tumor types. However, changes in lipid beta oxidation were observed in only the KRAS WT tumors. The non-clinical data presented here show a correlation between KRAS genotype and ixazomib sensitivity in NSCLC and colon xenografts and provide new evidence of regulation of key metabolic pathways by proteasome inhibition. |
| format | Article |
| id | doaj-art-1d976cb67df14d88a310d90883ff9f3f |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-1d976cb67df14d88a310d90883ff9f3f2025-08-20T02:15:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014482510.1371/journal.pone.0144825KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.Nibedita ChattopadhyayAllison J BergerErik KoenigBret BannermanJames GarnseyHugues BernardPaul HalesAngel Maldonado LopezYu YangJill DonelanKristen JordanStephen TirrellBradley StringerCindy XiaGreg HatherKatherine GalvinMark ManfrediNelson RhodesBen AmidonIn non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to ixazomib. In this study we examined factors responsible for ixazomib sensitivity or resistance using mouse xenograft models. A survey of 14 non-small cell lung cancer (NSCLC) and 6 colon xenografts showed a striking relationship between ixazomib activity and KRAS genotype; tumors with wild-type (WT) KRAS were more sensitive to ixazomib than tumors harboring KRAS activating mutations. To confirm the association between KRAS genotype and ixazomib sensitivity, we used SW48 isogenic colon cancer cell lines. Either KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cells to generate cells that stably express activated KRAS. SW48 KRAS WT tumors, but neither SW48-KRAS-G13D tumors nor SW48-KRAS-G12V tumors, were sensitive to ixazomib in vivo. Since activated KRAS is known to be associated with metabolic reprogramming, we compared metabolite profiling of SW48-WT and SW48-KRAS-G13D tumors treated with or without ixazomib. Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors. Ixazomib treatment resulted in significant metabolic regulation, and some of these changes were specific to KRAS WT tumors. Depletion of free amino acid pools and activation of GCN2-eIF2α-pathways were observed both in tumor types. However, changes in lipid beta oxidation were observed in only the KRAS WT tumors. The non-clinical data presented here show a correlation between KRAS genotype and ixazomib sensitivity in NSCLC and colon xenografts and provide new evidence of regulation of key metabolic pathways by proteasome inhibition.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144825&type=printable |
| spellingShingle | Nibedita Chattopadhyay Allison J Berger Erik Koenig Bret Bannerman James Garnsey Hugues Bernard Paul Hales Angel Maldonado Lopez Yu Yang Jill Donelan Kristen Jordan Stephen Tirrell Bradley Stringer Cindy Xia Greg Hather Katherine Galvin Mark Manfredi Nelson Rhodes Ben Amidon KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. PLoS ONE |
| title | KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. |
| title_full | KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. |
| title_fullStr | KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. |
| title_full_unstemmed | KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. |
| title_short | KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. |
| title_sort | kras genotype correlates with proteasome inhibitor ixazomib activity in preclinical in vivo models of colon and non small cell lung cancer potential role of tumor metabolism |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144825&type=printable |
| work_keys_str_mv | AT nibeditachattopadhyay krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT allisonjberger krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT erikkoenig krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT bretbannerman krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT jamesgarnsey krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT huguesbernard krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT paulhales krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT angelmaldonadolopez krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT yuyang krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT jilldonelan krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT kristenjordan krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT stephentirrell krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT bradleystringer krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT cindyxia krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT greghather krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT katherinegalvin krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT markmanfredi krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT nelsonrhodes krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism AT benamidon krasgenotypecorrelateswithproteasomeinhibitorixazomibactivityinpreclinicalinvivomodelsofcolonandnonsmallcelllungcancerpotentialroleoftumormetabolism |